Halozyme Therapeutics Inc... (HALO)
NASDAQ: HALO
· Real-Time Price · USD
54.00
-0.54 (-0.99%)
At close: Jun 13, 2025, 3:59 PM
54.04
0.07%
After-hours: Jun 13, 2025, 05:52 PM EDT
-0.99% (1D)
| Bid | 53.7 |
| Market Cap | 6.65B |
| Revenue (ttm) | 1.08B |
| Net Income (ttm) | 485.36M |
| EPS (ttm) | 3.76 |
| PE Ratio (ttm) | 14.36 |
| Forward PE | 7.6 |
| Analyst | Hold |
| Ask | 54.05 |
| Volume | 987,644 |
| Avg. Volume (20D) | 2,209,407 |
| Open | 53.75 |
| Previous Close | 54.54 |
| Day's Range | 53.77 - 54.52 |
| 52-Week Range | 42.01 - 70.51 |
| Beta | 1.19 |
About HALO
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol HALO
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for HALO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
-24.56%
Halozyme Therapeutics shares are trading lower aft...
Unlock content with
Pro Subscription
1 month ago
+18.12%
Halozyme Therapeutics shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 guidance. Also, Wells Fargo maintained an Equal-Weight rating on the stock and raised its price target from $60 to $65.
1 month ago · seekingalpha.com
Halozyme Therapeutics: Q1 Earnings Reveal A Bigger And Deeper MoatHalozyme Therapeutics reported strong Q1 2025 earnings with a 35% revenue increase, 54% net income growth, and raised full-year guidance, reinforcing its status as a top biotech growth story. Key grow...